Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics (IMDX) filed an 8-K on June 17, 2026 disclosing an officer departure, with related items also flagged for cost-of-living adjustment and financial statement changes. No cyber incidents were detected in the 90-day window, but a single material corporate event warrants deeper context. Our 90-day snapshot captures limited signal; the full Report extends analysis to 12 months of SEC filings, layers in dilution risk scoring and equity financing history, and surfaces AI-detected risk signals that may not appear in standard disclosures. The full $49 Report adds comprehensive officer movement tracking, capitalization impact assessment, and forward guidance on governance stability.